| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
DNA methyltransferases; nucleic acid hybridization. 5-Methyl-2'-O,4'-C-methylenecytidine is a cytidine nucleoside analog that inhibits DNA methyltransferases. The LNA modification (2'-O,4'-C-methylene bridge) locks the sugar conformation, enhancing binding affinity to complementary RNA or DNA. It has potential anti-metabolic and anti-tumor activities.
|
|---|---|
| ln Vitro |
5-Methyl-2'-O,4'-C-methylenecytidine demonstrates activity as a cytidine nucleoside analog in cellular assays. It inhibits DNA methyltransferases and has potential anti-metabolic and anti-tumor activities. The LNA modification enhances binding affinity. Detailed IC50 values have not been disclosed.
|
| ln Vivo |
In vivo activity of 5-Methyl-2'-O,4'-C-methylenecytidine has not been extensively characterized. As a cytidine analog and LNA nucleoside, it would be expected to have anti-tumor activity in animal models. The LNA modification may improve in vivo stability and efficacy.
|
| Enzyme Assay |
In vitro enzyme assays for DNA methyltransferase inhibition are performed using recombinant DNMT enzymes and DNA substrates. For LNA oligonucleotides, binding affinity is assessed by melting temperature (Tm) measurements. The compound is tested at varying concentrations in appropriate assays.
|
| Cell Assay |
Cells (e.g., cancer cell lines) are cultured and treated with 5-Methyl-2'-O,4'-C-methylenecytidine at concentrations typically ranging from 1–100 μM for 24–72 hours. DNA methylation levels are assessed by methylation-specific PCR. Cell viability and proliferation are evaluated by standard assays.
|
| Animal Protocol |
In vivo animal studies for 5-Methyl-2'-O,4'-C-methylenecytidine have not been reported. The compound is primarily used as a research tool for epigenetic and LNA studies. Future studies in animal models of cancer would be needed to evaluate in vivo efficacy.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 5-Methyl-2'-O,4'-C-methylenecytidine have not been published. The compound has a molecular weight of 269.25 and formula C11H15N3O5. As a cytidine analog and LNA nucleoside, it may have improved stability. In vivo PK parameters have not been characterized.
|
| Toxicity/Toxicokinetics |
Toxicology data for 5-Methyl-2'-O,4'-C-methylenecytidine have not been published. The compound is for research use only and not approved for human therapeutic applications. No systematic toxicological evaluation has been performed. Standard safety precautions should be observed.
|
| References |
[1]. Gowher H, et al. Mechanism of inhibition of DNA methyltransferases by cytidine analogs in cancer therapy. Cancer Biol Ther. 2004 Nov;3(11):1062-8.
|
| Additional Infomation |
4-Amino-1-[2,5-dehydro-4-(hydroxymethyl)-α-L-lythofuranyl]-5-methylcytosine is a pyrimidine nucleoside formed by the condensation of the N(1)-nitrogen of 4-amino-5-methylcytosine with 2,5-dehydro-4-(hydroxymethyl)-α-L-lythofuranyl. It is a nucleoside analog, pyrimidine nucleoside, and pyrimidinone. Its function is related to cytosine.
5-Methyl-2'-O,4'-C-methylenecytidine (CAS: 847650-87-7, molecular formula C11H15N3O5, molecular weight 269.25) is a cytidine nucleoside analog and LNA-related nucleoside. It inhibits DNA methyltransferases and has anti-tumor potential. It is not in clinical trials. |
| Molecular Formula |
C11H15N3O5
|
|---|---|
| Molecular Weight |
269.25
|
| Exact Mass |
269.101
|
| CAS # |
847650-87-7
|
| PubChem CID |
52946596
|
| Appearance |
White to off-white solid powder
|
| LogP |
-2.1
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
19
|
| Complexity |
491
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CC1=CN(C(=O)N=C1N)[C@H]2[C@H]3[C@@H]([C@@](O2)(CO3)CO)O
|
| InChi Key |
NELYIRACPIJATH-SZVQBCOZSA-N
|
| InChi Code |
InChI=1S/C11H15N3O5/c1-5-2-14(10(17)13-8(5)12)9-6-7(16)11(3-15,19-9)4-18-6/h2,6-7,9,15-16H,3-4H2,1H3,(H2,12,13,17)/t6-,7+,9-,11+/m1/s1
|
| Chemical Name |
4-amino-1-[(1S,3R,4R,7S)-7-hydroxy-1-(hydroxymethyl)-2,5-dioxabicyclo[2.2.1]heptan-3-yl]-5-methylpyrimidin-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7140 mL | 18.5701 mL | 37.1402 mL | |
| 5 mM | 0.7428 mL | 3.7140 mL | 7.4280 mL | |
| 10 mM | 0.3714 mL | 1.8570 mL | 3.7140 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
